A new study has been published in the prestigious nature.com website, completed by a whole range of scientists, but more importantly looks to be somewhat led by Gianpietro Dotti, who sits on our scientific advisory board. I will try summarise the article below, but is a very interesting and promising read and demonstrates the potential that iNKT cell therapy will far superior in the treatment of solid tumours vs CAR-T treament.
Abstract:
"Human natural killer T (NKT) cells have been proposed as a promising cell platform for chimeric antigen receptor (CAR) therapy in solid tumors. Here we generated murine CAR-NKT cells and compared them with CAR-T cells in immune-competent mice. Both CAR-NKT cells and CAR-T cells showed similar antitumor effects in vitro, but CAR-NKT cells showed superior antitumor activity in vivo via CD1d-dependent immune responses in the tumor microenvironment. Specifically, we show that CAR-NKT cells eliminate CD1d-expressing M2-like macrophages. In addition, CAR-NKT cells promote epitope spreading and activation of endogenous T cell responses against tumor-associated neoantigens. Finally, we observed that CAR-NKT cells can co-express PD1 and TIM3 and show an exhaustion phenotype in a model of high tumor burden. PD1 blockade as well as vaccination augmented the antitumor activity of CAR-NKT cells. In summary, our results demonstrate the multimodal function of CAR-NKT cells in solid tumors, further supporting the rationale for developing CAR-NKT therapies in the clinic
Results:
CAR-NKT cells target tumour cells in vitro
"Collectively, these data show that muribe CAR-NKT cells can target tumour cells via CAR expression"
CAR-NKT cells have superior anittumour activity to CAR-T cells in vivo"Collectively, these data show that CAR-NKT cells control tumour growth more effectively than CAR-T cells in vivo"
CAR-NKT cells reprogram the TME and reduce M2-like macrophages in a CD1d-dependent manner"Overall, these data indicate that CAR-NKT cells mediate superior antitumor functionality compared with CAR-T cells and that this activity is mediated at least in part by the selective CD1d-dependent reduction of M2-like macrophages, while CD1d low-expressing M1-like macrophages are spared"
CAR-NKT cells promote endogenous T Cell responses by activating DCs"Overall, these data demonstrate that PD1 blockade and vaccination further enhance the antitumor efficacy of CAR-NKT cells"
Discussion:
"In summary, our data show that CAR-NKT cells possess the unique ability to target both tumour cells and immunosuppressive M2-like macrophages. In addition, we also demonstrated that CAR-NKT cells can promote endogenous T cell responces to neoantigens in solid tumours by mediating CD1d-dependant activation of DCs. Finally, PD1 blockade and vaccination enhance CAR-NKT antitumor activity. Collectively, our results demonstrate the multimodal action of CAR-NKT cells in solid tumours, further supporting their exploration in clinical studies"
article: https://www.nature.com/articles/s43018-024-00830-0
Summary from Matthew Baker (Blue Ocean Equities): https://www.linkedin.com/feed/update/urn:li:activity:7251049572712505346/
- Forums
- ASX - By Stock
- CAR-NKT cells demonstrate superior antitumor activity to CAR-T cells
ALA
arovella therapeutics limited
Add to My Watchlist
5.00%
!
10.5¢

A new study has been published in the prestigious nature.com...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $124.8M |
Open | High | Low | Value | Volume |
10.0¢ | 10.5¢ | 10.0¢ | $21.83K | 212.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 443503 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 424264 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 385727 | 0.100 |
2 | 54811 | 0.099 |
6 | 170539 | 0.098 |
3 | 146855 | 0.097 |
1 | 105000 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 424264 | 6 |
0.110 | 865044 | 6 |
0.115 | 216947 | 3 |
0.120 | 170451 | 6 |
0.125 | 310476 | 3 |
Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
Featured News
ALA (ASX) Chart |